We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Trial design of the MOTheR HDx study: a multicenter, open-label, prospective, randomized study to explore the morbidity and mortality in patients dialyzed with the Theranova HDx in comparison with online hemodiafiltration.
- Authors
Sequera, Patricia de; Pérez-García, Rafael; Vega, Almudena; Martínez-Vaquera, Shaira; Acosta, Jesús Guillermo; Valle, Katia Pérez Del; Fernández-Lucas, Milagros; García-Rubiales, María Antonia; García-Herrera, Antonio Luis; Coll, Elisabeth; Mérida, Evangelina; Martínez-Miguel, Patricia; Castaño, Itziar; Gil-Casares, Beatriz; Garro, Julia; Maduell, Francisco; network, the MOTheR collaborative
- Abstract
Background Dialysis patients have been maintaining a high rate of cardiovascular morbidity and mortality. For this reason, it is to introduce necessary new technical advances in clinical practice. There is a relation between toxins retention and inflammation, mortality and morbidity. Medium cut-off (MCO) membranes are a new generation of membranes that allow the removal of a greater number of medium-sized molecules compared with high-flux hemodialysis (HF-HD), but retaining albumin. MCO membranes have an increased permeability and the presence of internal filtration. Because of these special properties, MCO generated a new concept of therapy called expanded HD (HDx). Until now, online hemodiafiltration (OL-HDF) has demonstrated its superiority, in terms of survival, compared with HF-HD. However, the comparison between OL-HDF and HDx remains an unsolved question. Methods The MOTheR HDx study trial (NCT03714386) is an open-label, multicenter, prospective, 1:1 randomized, parallel-group trial designed to evaluate the efficacy and safety of HDx compared with OL-HDF in patients treated for dialysis in Spain for up to 36 months. The main endpoint is to determinate whether HDx is non inferior to OL-HDF at reducing the combined outcome of all-cause death and stroke (ischemic or hemorrhagic), acute coronary syndrome (angina and myocardial infarction), peripheral arterial disease (amputation or revascularization) and ischemic colitis (mesenteric thrombosis). Results The trial has already started.
- Subjects
SPAIN; HEMODIAFILTRATION; MYOCARDIAL infarction; ACUTE coronary syndrome; PERIPHERAL vascular diseases; ISCHEMIC colitis; HEMODIALYSIS patients; MORTALITY
- Publication
Clinical Kidney Journal, 2023, Vol 16, Issue 11, p2254
- ISSN
2048-8505
- Publication type
Article
- DOI
10.1093/ckj/sfad128